在囊性纤维化临床试验中整合外部控制的统计方法:模拟和应用
Mark N Warden1,2, Sonya L Heltshe1,3, Noah Simon1,4
1Cystic Fibrosis Therapeutics Development Network Coordinating Center, Seattle Children's Hospital, Seattle, WA 98145, United States.
American journal of epidemiology
|June 25, 2024
概括
在临床试验中使用外部对照可以减少患有囊性纤维化等罕见疾病的患者数量. 相应的先前方法在真实数据中表现最好,为药物开发提供了有前途的方法.
科学领域:
- 临床试验 临床试验
- 药学流行病学 药学流行病学
- 生物统计学 生物统计学
背景情况:
- 针对囊性纤维化等罕见疾病的药物开发在临床试验的患者招募方面面临挑战.
- 历史试验的外部控制可以减轻对大型前性研究的需求,帮助监管部门批准罕见疾病干预措施.
研究的目的:
- 评估将外部对照纳入囊性纤维化治疗临床试验的统计方法.
- 为了比较反向概率权重的性能,贝叶斯模型使用权力先验,和等级贝叶斯模型使用相应先验.
主要方法:
- 该研究采用模拟研究和对真实临床试验数据的分析.
- 评估了三种统计方法:反向概率加权,贝叶斯建模以倾向得分为基础的权力先验和等级贝叶斯建模以相应先验.
主要成果:
- 所有评估的方法在治疗效果估计中显示出最小的偏差 (少于4%).
- I型错误率一般低于5%.
- 相应的先前方法与真实临床试验数据显示出更高的性能,而反向概率加权显示出对共变频率差异的敏感性.
结论:
- 整合外部控制提供了一个可行的策略,以减少罕见疾病的临床试验大小,可能加速治疗的发展.
- 相应的前贝叶斯方法是有效利用临床试验环境中的外部控制的有希望的方法.
- 这种方法可以显著提升针对罕见疾病的新疗法的管道.
更多相关视频
07:04Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
Published on: February 11, 2017
19.2K
08:00Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
Published on: April 11, 2018
10.7K
相关概念视频
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
125
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
125
01:24Cystic Fibrosis: Management
154
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
154